Pharmacognosy Magazine

ORIGINAL ARTICLE
Year
: 2015  |  Volume : 11  |  Issue : 42  |  Page : 404--409

Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B Pathway


Xiang-An Zhang1, Shuangxi Zhang1, Qing Yin2, Jing Zhang1,  
1 Anorectal Disease Center, The First Affiliated Hospital, Henan College of TCM, Zhengzhou 450000, China
2 Department of Hematological Malignancy, The Affiliated Hospital, Henan TCM Research Academy, Zhengzhou 450000, China

Correspondence Address:
Xiang-An Zhang
Anorectal Disease Center, The First Affiliated Hospital, Henan College of TCM, No. 19, Renmin Road, Zhengzhou 450000
China

Abstract

Quercetin can inhibit the growth of cancer cells with the ability to act as chemopreventers. Its cancer-preventive effect has been attributed to various mechanisms, including the induction of cell-cycle arrest and/or apoptosis as well as the antioxidant functions. Nuclear factor kappa-B (NF-kB) is a signaling pathway that controls transcriptional activation of genes important for tight regulation of many cellular processes and is aberrantly expressed in many types of cancer. Inhibitors of NF-kB pathway have shown potential anti-tumor activities. However, it is not fully elucidated in colon cancer. In this study, we demonstrate that quercetin induces apoptosis in human colon cancer CACO-2 and SW-620 cells through inhibiting NF-kB pathway, as well as down-regulation of B-cell lymphoma 2 and up-regulation of Bax, thus providing basis for clinical application of quercetin in colon cancer cases.



How to cite this article:
Zhang XA, Zhang S, Yin Q, Zhang J. Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B Pathway.Phcog Mag 2015;11:404-409


How to cite this URL:
Zhang XA, Zhang S, Yin Q, Zhang J. Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-kappa B Pathway. Phcog Mag [serial online] 2015 [cited 2022 Aug 15 ];11:404-409
Available from: http://www.phcog.com/text.asp?2015/11/42/404/153096


Full Text

 INTRODUCTION



Colon cancer is one of the most prevalent cancers throughout the world and especially in the Western countries. Many epidemiological studies indicated that western style diet such as consumption of red meats is possibly associated with a high colon cancer incidence. [1] Despite earlier detection and dropping death rates in colon cancer, 112,340 new cases were estimated for 2007. [2] The most common treatment for colon and rectal cancer is surgical resection, followed by adjuvant therapy with 5-fluorouracil, oxaliplatin, and leucovorin. Early detection can provide a 5-year survival rate of up to 90%, and surgery is most often curative. However, if patients present with distant metastasis at the time of diagnosis, the 5-year survival rate drops to only 10%. [2] Despite recent improvements in surgical techniques and chemotherapy, advanced colon cancer continues to have poor clinical outcomes. Molecules intimately related to cancer cell survival, proliferation, invasion, and metastasis have been studied as candidates for molecular targeted agents. [3]

Dietary polyphenolic compounds have showed various pharmacological activities including anti-cancer activity. [4],[5],[6],[7],[8],[9],[10] Quercetin (3,3',4',5,7-pentahydroxyflavone) [Figure 1]a, an important dietary polyphenol present in red onions, apples, berries, citrus fruits, tea, and red wine, [11] exhibits anti-oxidant, anti-inflammatory, anti-obesity and anti-cancer properties. [12] Quercetin has received increasing attention as a pro-apoptotic flavonoid with specific and almost exclusive activity on tumor cells rather than normal, nontransformed cells. [13],[14] However, the mechanisms by which quercetin exerts its anti-cancer activity remain unclear.{Figure 1}

The nuclear factor-kappa B (NF-kB) pathway is thought to play an important role in the process leading from inflammation to carcinogenesis and thus may be a candidate for targeted intervention. [15],[16],[17] Multiple pro-inflammatory stimuli activate NF-kB, primarily through inhibitor of kB kinase (IKK)-dependent phosphorylation and ubiquitin-mediated degradation of IkB proteins. Once activated, NF-kB stimulates the transcription of genes encoding cytokines, growth factors, chemokines, and anti-apoptotic factors. [18],[19] Moreover, NF-kB pathway has also been implicated in tumor initiation, progression, metastasis, and resistance to chemotherapy. [17],[20] In colon cancer, NF-kB is constitutively activated. [21],[22] Aberrant NF-kB activation results in enhanced proliferation, [23] evasion of apoptosis, [23],[24],[25] genomic instability, [26] increased rate of glycolysis [27] and drug resistance [28] in colon cancer cells.

Studies have suggested a series of pharmacologic inhibitors of NF-kB pathway to be potential anti-cancer agents, [20],[29] such as IkB or IKK inhibitors, [30] ammonium pyrrolidinedithiocarbamate, [31] as well as selective ubiquitin proteosome inhibitors. [32] However, there still has no comprehensive investigation for anti-tumor effect of NF-kB inhibitors on colon cancer.

Our present study demonstrated that quercetin presented potent anticancer effects within an inhibitory effect on NF-kB, and could induce apoptosis of colon cancer cells in vitro, thus providing basis for clinical application of quercetin in colon cancer cases.

 MATERIALS AND METHODS



Reagents and antibodies

Quercetin, glyceraldehyde 3-phosphate dehydrogenase was purchased from Sigma Chemical Co (St. Louis, MO, USA). Antibodies including phosphorylated and nonphosphorylated forms of IkB-α and NF-kB were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum were purchased from GIBCO BRL.

Cell culture

Human colon cancer CACO-2 and SW-620 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were incubated in DMEM (high glucose), 10% fetal bovine calf serum, 100 U/ml penicillin-streptomycin. Cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 .

Cell viability assay

Cell viability was quantified by Cell Counting Kit-8 (CCK-8) (Beyotime, China) assay according to the manufacturer's instructions. In brief, CACO-2 and SW-620 cells were seeded into 96-well plates at a density of 2 × 10 3 cells/well. After incubation overnight, cells were treated as indicated concentration of quercetin and assessed by CCK-8 assay at 6 and 24 h respectively. 10 μl of CCK-8 reagent was added to each well and incubated for 1 h. The difference in absorbance between 450 and 630 nm was measured by a microplate reader (BioTek, Winooski, VT, USA) as an indicator of cell viability. Independent experiments were done in triplicate. About 50% growth inhibitory concentration (IC 50 ) values were calculated as the concentration of the compound that inhibited the viability of cells by 50% as compared with control cells grown in the absence of inhibitor.

Cell lysis and immunoblotting

Cells were lysed, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane (Immobilon; Millipore, Billerica, MA). Immunoblotting was done with different antibodies and visualized by an enhanced chemiluminescence (Amersham, Piscataway, NJ) method.

Nuclear factor kappa-B transcription factor assay

Nuclear factor kappa-B (NF-kB) p65 subunit DNA binding activity was determined by an enzyme-linked immunosorbent assay (Cayman Chemicals, Ann Arbor, MN, USA) according to the manufacturer's instructions. In brief, a specific double stranded DNA sequence containing the NF-kB (p65) response element was immobilized onto the bottom of wells of a 96-well plate. Nuclear extracts were added to the plate and incubated overnight at 4°C without agitation NF-kB (p65) was detected by addition of a specific primary antibody directed against p65. A secondary antibody conjugated to horseradish peroxidase was added to provide a sensitive colorimetric readout at 450 nm. Independent experiments were done in triplicate. Nuclear extract from cells was prepared using Nuclear Extraction Kit (Millipore, Watford, UK) according to manufacturer's instructions.

Hoechst-33258 staining

CACO-2 and SW-620 cells were seeded in 12-well culture dishes (5 × 10 4 cells/well). After experimental treatment, cells were washed twice with phosphate buffered solution (PBS), and stained with Hoechst-33258 (5 mg/ml) for 5 min in the dark, and then followed by extensive washes. Nuclear staining was examined under a fluorescence microscope, and images were captured using ImagePro Plus software (Media Cybernetics, Silver spring, MD).

Cell apoptosis assay

Cell apoptosis detection was performed using an Annexin-V-FITC Apoptosis Detection Kit (BD company, US) according to the manufacturer's protocol. Briefly, cells were collected after 24 h treatment with quercetin. The cells were washed twice with cold PBS then resuspended in 1 × binding buffer at a concentration of 1 × 10 6 cells/ml. Then 500 μl cell suspension was incubated with 5 μl Annexin-V-FITC and 10 μl PI for 15 min in the dark and analyzed by a FACScalibur instrument (Becton Dickinson, San Jose, US) within 1 h. Apoptotic cells were those stained with Annexin V + /PI− (early apoptosis) plus Annexin V+/PI+ (late apoptosis).

Statistical analysis

Results were presented as mean ± standard deviation differences between two groups were tested using Student's t-test; two-way analysis of variance analysis was performed where indicated. Statistical significance was determined at the level of P < 0.05.

 RESULTS



Inhibitory effects of quercetin on viability of human colon cancer cells in vitro

To identify whether quercetin influence the survival of CACO-2 and SW-620 cells, cells were treated with 0-200 μM quercetin, and after that cell viability was examined by CCK-8 assay. As shown in [Figure 1]b, both CACO-2 and SW-620 cells viability are dramatically suppressed after treating with 200 μM quercetin, when compared to the negative control (0 μM). After 24 h, quercetin showed high inhibition of cell population growth in a dose-dependent manner with IC 50 values of 35 μM (CACO-2 cells) and 20 μM (SW-620 cells).

Inhibitory effect of quercetin on nuclear factor kappa-B activity in colon cancer cells

We further detected the inhibitory effect of quercetin on NF-kB activity in CACO-2 and SW-620 cells. As shown in [Figure 2], NF-kB DNA binding activity was dramatically decreased after quercetin treatment for 6 h. Moreover, quercetin also induced the dephosphorylation and up-regulation of IkB-α [Figure 3]. Taken together, these results suggested that quercetin displayed rapid and potent anti-tumor effects against colon cancer cell lines.{Figure 2}{Figure 3}

Quercetin induced CACO-2 and SW-620 cells apoptosis

The apoptotic effect of quercetin was analyzed and quantified by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit. As shown in [Figure 4], quercetin induced CACO-2 and SW-620 cells apoptosis in a dose-dependent manner.{Figure 4}

Apoptotic events of Hoechst-33258 staining were also tested. After exposed to three concentrations of quercetin (0 μM, 25 μM and 50 μM) for 24 h, apoptosis of CACO-2 and SW-620 cells was demonstrated by Hoechst-33258 staining, revealed cell membrane permeability increasement and nuclear condensation [Figure 5].{Figure 5}

In order to gain a better insight into pro-apoptotic effect of quercetin, we detected protein expression of apoptosis marker molecular. Poly (ADP-ribose) polymerase (PARP) was one of the main cleavage targets of caspase-3 and cleaved PARP always served as a marker of cells undergoing apoptosis. [33] Results demonstrated that cleaved PARP could not be detected until quercetin treated was administrated at the high dose of 30 μM, further suggesting that quercetin could induce apoptosis in a dose-dependent manner [Figure 6]. We also measured the expression of apoptosis inducing factor (AIF), which played a critical role in caspase-independent apoptosis. [34] However, results demonstrated that no increase in AIF expression was detected after quercetin treatment [Figure 6].{Figure 6}

B-cell lymphoma 2 family proteins were involved with quercetin induced apoptosis

We next investigated the expression of B-cell lymphoma 2 (Bcl-2) families, which regulated mitochondrial apoptosis and could be separated into pro-survival members (such as Bcl-2, Bcl-extra large (Bcl-xL), and myeloid cell leukemia-1), as well as pro-apoptotic proteins (such as Bax). [35],[36] As shown in [Figure 7], after quercetin treatment, Bcl-2 is down-regulated significantly, and Bax is up-regulated on the contrary. These results are consisted with the general notion that Bcl-2 and Bax play a pivotal role in regulating mitochondrial apoptosis pathway. [37]{Figure 7}

 DISCUSSION



Dietary phytochemicals consist of a wide variety of biologically active compounds that are ubiquitous in plants, many of which have been reported to have anti-tumor properties. Epidemiological studies have shown that the consumption of vegetable, fruits, and tea is associated with a decreased risk of cancer and cardiovascular diseases, and polyphenols are believed to play an important role in preventing these diseases. [38],[39] Among them, quercetin has been reported to have therapeutic potential for treating many human cancers. [11],[12],[13],[14]

An enormous amount of data strongly implicate that the inhibition of NF-kB signaling could be potentially effective in suppressing inflammation or tumor progression, and development of new small molecule inhibitors of this pathway is needed. [40],[41] Recently, studies have been made in the design of potent orally active NF-kB pathway inhibitors for anti-inflammation or anti-tumor purposes. [42],[43],[44],[45] Compounds that inhibited the NF-kB pathway could lead to the decreased expression of endothelial cell adhesion molecules. [46] Further studies searching for alternative therapeutic strategies against malignancies have shown that it is a potent inducer of apoptosis in a number of malignant cells such as in colorectal cancer, [47] breast cancer, [48] and hematological malignants. [49],[50],[51] In this study, we showed the potent anti-tumor effects of quercetin as a novel NF-kB inhibitor against human colon cancer in vitro.

In colon cancer cells, NF-kB is always constitutively activated, [21],[22] and contributes to enhanced proliferation [23] and evasion of apoptosis. [23],[24],[25] Degradation of IkB release NF-kB proteins to the nucleus where they transactivate approximately 300 target genes, including those encoding regulators of pro-survival factors, such as Bcl-2, [52] Bcl-xL. [40] NF-kB is an important inhibitor of apoptosis and can protect cancer cells from cell death induced by tumor necrosis factors (TNFα) or TNF superfamily members, different pharmaceuticals or irradiation. [53] In this study, we found that quercetin could down-regulate Bcl-2 as well as up-regulate Bax, which may contribute to this apoptosis induction. However, the exact mechanism how quercetin induces mitochondrial dysfunction and cellular apoptosis also needs further investigation.

 CONCLUSIONS



Quercetin could induce human colon cancer cells apoptosis via inhibiting NF-kB pathway. Since quercetin showed potent inhibition on the proliferation of human colon cancer cells, it had the potential to be developed into a drug candidate for treating human colon cancers.

References

1Boateng J, Verghese M, Shackelford L, Walker LT, Khatiwada J, Ogutu S, et al. Selected fruits reduce azoxymethane (AOM)-induced aberrant crypt foci (ACF) in Fisher 344 male rats. Food Chem Toxicol 2007;45:725-32.
2Fuller-Pace FV. The DEAD box proteins DDX5 (p68) and DDX17 (p72): Multi-tasking transcriptional regulators. Biochim Biophys Acta 2013;1829:756-63.
3Patil JR, Jayaprakasha GK, Chidambara Murthy KN, Tichy SE, Chetti MB, et al. Apoptosis-mediated proliferation inhibition of human colon cancer cells by volatile principles of Citrus aurantifolia. Food Chem 2009;114:1351-8.
4Fan H, Wu D, Tian W, Ma X. Inhibitory effects of tannic acid on fatty acid synthase and 3T3-L1 preadipocyte. Biochim Biophys Acta 2013;1831:1260-6.
5Wu D, Ma X, Tian W. Pomegranate husk extract, punicalagin and ellagic acid inhibit fatty acid synthase and adipogenesis of 3T3-L1 adipocyte. J Funct Food 2013;5:633-41.
6Wang Y, Tian WX, Ma XF. Inhibitory effects of onion (Allium cepa L.) extract on proliferation of cancer cells and adipocytes via inhibiting fatty acid synthase. Asian Pac J Cancer Prev 2012;13:5573-9.
7Quan X, Wang Y, Ma X, Liang Y, Tian W, Ma Q, et al. A-Mangostin induces apoptosis and suppresses differentiation of 3T3-L1 cells via inhibiting fatty acid synthase. PLoS One 2012;7:e33376.
8Jiang HZ, Quan XF, Tian WX, Hu JM, Wang PC, Huang SZ, et al. Fatty acid synthase inhibitors of phenolic constituents isolated from Garcinia mangostana. Bioorg Med Chem Lett 2010;20:6045-7.
9Li P, Tian W, Wang X, Ma X. Inhibitory effect of desoxyrhaponticin and rhaponticin, two natural stilbene glycosides from the Tibetan nutritional food Rheum tanguticum Maxim. ex Balf. on fatty acid synthase and human breast cancer cells. Food Funct 2014;5:251-6.
10Jiang HZ, Ma QY, Fan HJ, Liang WJ, Huang SZ, Dai HF, et al. Fatty acid synthase inhibitors isolated from Punica granatum L. J Braz Chem Soc 2012;23:889-93.
11Erlund I. Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004;24:851-74.
12Gibellini L, Pinti M, Nasi M, Montagna JP, De Biasi S, Roat E, et al. Quercetin and cancer chemoprevention. Evid Based Complement Alternat Med 2011;2011:591356.
13Park MH, Min do S. Quercetin-induced downregulation of phospholipase D1 inhibits proliferation and invasion in U87 glioma cells. Biochem Biophys Res Commun 2011;412:710-5.
14Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, et al. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1a in tumor and normal cells. Cancer Chemother Pharmacol 2010;65:277-87.
15DiDonato JA, Mercurio F, Karin M. NF-kB and the link between inflammation and cancer. Immunol Rev 2012;246:379-400.
16Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
17Perkins ND. The diverse and complex roles of NF-kB subunits in cancer. Nat Rev Cancer 2012;12:121-32.
18Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109 Suppl:S81-96.
19Kanarek N, Ben-Neriah Y. Regulation of NF-kB by ubiquitination and degradation of the IkBs. Immunol Rev 2012;246:77-94.
20Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
21Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, et al. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-42.
22Wu L, Pu Z, Feng J, Li G, Zheng Z, Shen W. The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma. J Surg Oncol 2008;97:439-44.
23Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 2008;135:2030-42, 2042.e1.
24Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Rho/Rhotekin-mediated NF-kappaB activation confers resistance to apoptosis. Oncogene 2004;23:8731-42.
25Sakamoto K, Hikiba Y, Nakagawa H, Hayakawa Y, Yanai A, Akanuma M, et al. Inhibitor of kappaB kinase beta regulates gastric carcinogenesis via interleukin-1alpha expression. Gastroenterology 2010;139:226-38.e6.
26Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-6.
27Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, et al. Warburg effect revisited: An epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010;29:442-50.
28Cho SJ, Park JW, Kang JS, Kim WH, Juhnn YS, Lee JS, et al. Nuclear factor-kappaB dependency of doxorubicin sensitivity in gastric cancer cells is determined by manganese superoxide dismutase expression. Cancer Sci 2008;99:1117-24.
29Zanotto-Filho A, Braganhol E, Schröder R, de Souza LH, Dalmolin RJ, Pasquali MA, et al. NFêB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011;81:412-24.
30Meng Z, Lou S, Tan J, Xu K, Jia Q, Zheng W. Nuclear factor-kappa B inhibition can enhance apoptosis of differentiated thyroid cancer cells induced by 131I. PLoS One 2012;7:e33597.
31Li Q, Yu YY, Zhu ZG, Ji YB, Zhang Y, Liu BY, et al. Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines. Eur Surg Res 2005;37:105-10.
32Zaidi SF, Yamamoto T, Refaat A, Ahmed K, Sakurai H, Saiki I, et al. Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter 2009;14:588-95.
33Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly (ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998;273:33533-9.
34Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147-50.
35Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009;138:838-54.
36Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell 2011;147:742-58.
37Tait SW, Green DR. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010;11:621-32.
38Liang Y, Tian W, Ma X. Inhibitory effects of grape skin extract and resveratrol on fatty acid synthase. BMC Complement Altern Med 2013;13:361.
39Fan H, Tian W, Ma X. Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase. Target Oncol 2014;9:279-86.
40Fuchs O. Transcription factor NF-kB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol 2010;3:98-122.
41Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-47.
42Murata T, Shimada M, Kadono H, Sakakibara S, Yoshino T, Masuda T, et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity. Bioorg Med Chem Lett 2004;14:4013-7.
43Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005;145:178-92.
44Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
45Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006;7:1341-7.
46Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103.
47Fernández-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytés A, et al. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci U S A 2007;104:276-81.
48Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007;102:157-72.
49Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96:2537-42.
50Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002;100:1828-34.
51Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 2007;26:1166-77.
52Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001;20:7342-51.
53Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: Balancing life and death - A new approach to cancer therapy. J Clin Invest 2005;115:2625-32.